Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients.

about

Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.

P2860

Q50135771-54C297DD-B278-44BC-AFA8-C035959615F6

P2860

Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients.

Item

http://www.wikidata.org/entity/Q47823030

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@en

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@nl

type

Item

label

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@en

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@nl

prefLabel

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@en

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@nl

P1476

Osteoprotegerin Is the Stronge ...... Peritoneal Dialysis Patients.

@en

P2093

Carmen Mora

http://www.w3.org/2001/XMLSchema#string

Marcela Avila

http://www.w3.org/2001/XMLSchema#string

María Del Carmen Prado

http://www.w3.org/2001/XMLSchema#string

Mexican Collaborative Group

http://www.w3.org/2001/XMLSchema#string

Miriam Zavala

http://www.w3.org/2001/XMLSchema#string

Ramón Paniagua

http://www.w3.org/2001/XMLSchema#string

P2860

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies

Management of hyperphosphataemia in chronic kidney disease-challenges and solutions

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients

High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis.

Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis.

Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?

Osteoprotegerin, vascular calcification and atherosclerosis.

Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.

Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?

P304

39-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000477380

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28614819

http://www.w3.org/2001/XMLSchema#string

Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients.

about

P2860

P2860

Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698